{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:38:10Z","timestamp":1792564690915,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Provide expert-informed guidance on the integration of aflibercept 8\u2009mg into routine clinical care for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO), based on clinical trial and real-world evidence. Sixteen retina specialists (\u2018experts\u2019) met during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in May 2025 to discuss the clinical use of aflibercept 8\u2009mg. A post-meeting online platform was used to collect additional independent input. Agreement was captured using binary responses and categorised as: all agreed (100%), majority agreed (\u2009\u2265\u200975%), most agreed (50\u201374%), or non-consensus (\u2009\u2264\u200950%). All experts agreed that aflibercept 8\u2009mg may be considered as a first-line treatment in treatment-na\u00efve patients with nAMD and DMO, and switching to aflibercept 8\u2009mg can be considered for previously treated patients. The majority of experts agreed that switching patients with well-controlled disease on shorter or intermediate dosing intervals may enable further interval extension while maintaining disease control, and switching patients with poorly controlled disease may optimise anatomical outcomes and improve stability. Most experts agreed that three initial monthly loading doses are appropriate in newly diagnosed patients. No consensus was reached on optimal dosing-decision strategies after switching in patients with poorly controlled disease, nor on the timing of initial interval modification during treatment initiation. These expert opinions, informed by available, emerging clinical evidence and real-world clinical experience, support aflibercept 8\u2009mg as a first-line and switch option for nAMD and DMO, using personalised treatment approaches for both treatment-na\u00efve and previously treated patients.<\/jats:p>","DOI":"10.1038\/s41433-026-04779-5","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:29:21Z","timestamp":1786116561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aflibercept 8\u2009mg in neovascular age-related macular degeneration and diabetic macular oedema: Translating clinical trials into clinical practice"],"prefix":"10.1038","author":[{"given":"Sobha","family":"Sivaprasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-9535","authenticated-orcid":false,"given":"Jean-Francois","family":"Korobelnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0213-6253","authenticated-orcid":false,"given":"Richard","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6227-2242","authenticated-orcid":false,"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-8143","authenticated-orcid":false,"given":"Javier","family":"Zarranz-Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-1264","authenticated-orcid":false,"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-9272","authenticated-orcid":false,"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1165","authenticated-orcid":false,"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"4779_CR1","unstructured":"World Health Organization. Ageing and health. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health."},{"key":"4779_CR2","unstructured":"World Health Organization. Diabetes. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"4779_CR3","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","volume":"9","author":"MJ Burton","year":"2021","unstructured":"Burton MJ, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9:e489\u2013e551. https:\/\/doi.org\/10.1016\/S2214-109X(20)30488-5.","journal-title":"Lancet Glob Health"},{"key":"4779_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaophthalmol.2013.7647","volume":"132","author":"FA Sloan","year":"2014","unstructured":"Sloan FA, Hanrahan BW. The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration. JAMA Ophthalmol. 2014;132:456\u201363. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.7647.","journal-title":"JAMA Ophthalmol"},{"key":"4779_CR5","doi-asserted-by":"publisher","unstructured":"Nguyen QD, Moshfeghi AA, Lim JI, Ponomareva E, Chauhan A, Rao R, et al. Simulation of long-term impact of intravitreal anti-VEGF therapy on patients with severe non-proliferative diabetic retinopathy. BMJ Open Ophthalmol. 2023;8-15, https:\/\/doi.org\/10.1136\/bmjophth-2022-001190.","DOI":"10.1136\/bmjophth-2022-001190"},{"key":"4779_CR6","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702.","journal-title":"Br J Ophthalmol"},{"key":"4779_CR7","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2024.12.018","volume":"132","author":"GA Vemulakonda","year":"2025","unstructured":"Vemulakonda GA, et al. Age-Related Macular Degeneration Preferred Practice Pattern\u00ae. Ophthalmology. 2025;132:P1\u2013P74. https:\/\/doi.org\/10.1016\/j.ophtha.2024.12.018.","journal-title":"Ophthalmology"},{"key":"4779_CR8","doi-asserted-by":"publisher","first-page":"P75","DOI":"10.1016\/j.ophtha.2024.12.020","volume":"132","author":"JI Lim","year":"2025","unstructured":"Lim JI, et al. Diabetic Retinopathy Preferred Practice Pattern\u00ae. Ophthalmology. 2025;132:P75\u2013P162. https:\/\/doi.org\/10.1016\/j.ophtha.2024.12.020.","journal-title":"Ophthalmology"},{"key":"4779_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222. https:\/\/doi.org\/10.1159\/000458539.","journal-title":"Ophthalmologica"},{"key":"4779_CR10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(18)31550-2.","journal-title":"Lancet"},{"key":"4779_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41572-025-00646-x","volume":"11","author":"S Sivaprasad","year":"2025","unstructured":"Sivaprasad S, Wong TY, Gardner TW, Sun JK, Bressler NM. Diabetic retinal disease. Nat Rev Dis Prim. 2025;11:62. https:\/\/doi.org\/10.1038\/s41572-025-00646-x.","journal-title":"Nat Rev Dis Prim"},{"key":"4779_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2025.101406","volume":"109","author":"DSC Ng","year":"2025","unstructured":"Ng DSC, et al. International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME). Prog Retin Eye Res. 2025;109:101406. https:\/\/doi.org\/10.1016\/j.preteyeres.2025.101406.","journal-title":"Prog Retin Eye Res"},{"key":"4779_CR13","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.15201","volume":"101","author":"RP Gale","year":"2023","unstructured":"Gale RP, et al. The management of neovascular age-related macular degeneration: A systematic literature review of patient-reported outcomes, patient mental health and caregiver burden. Acta Ophthalmol. 2023;101:e26\u2013e42. https:\/\/doi.org\/10.1111\/aos.15201.","journal-title":"Acta Ophthalmol"},{"key":"4779_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40123-024-01061-3","volume":"14","author":"A Loewenstein","year":"2025","unstructured":"Loewenstein A, et al. Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration. Ophthalmol Ther. 2025;14:211\u201328. https:\/\/doi.org\/10.1007\/s40123-024-01061-3.","journal-title":"Ophthalmol Ther"},{"key":"4779_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: A mixed-methods systematic review. Ophthalmology. 2021;128:234\u201347. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.060.","journal-title":"Ophthalmology"},{"key":"4779_CR16","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, et al. Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020;258:2077\u201390.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4779_CR17","doi-asserted-by":"publisher","unstructured":"Holz FG, et al. Adherence to Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: 24-Month Results from the ANDROMEDA Study. Ophthalmol Retina 2025; https:\/\/doi.org\/10.1016\/j.oret.2025.09.004.","DOI":"10.1016\/j.oret.2025.09.004"},{"key":"4779_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, et al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the Phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141:834\u201342. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2421.","journal-title":"JAMA Ophthalmol"},{"key":"4779_CR19","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/pharmaceutics15051416","volume":"15","author":"D Veritti","year":"2023","unstructured":"Veritti D, Sarao V, Di Bin F, Lanzetta P. Pharmacokinetic and pharmacodynamic rationale for extending VEGF inhibition increasing intravitreal aflibercept dose. Pharmaceutics. 2023;15:1416. https:\/\/doi.org\/10.3390\/pharmaceutics15051416.","journal-title":"Pharmaceutics"},{"key":"4779_CR20","doi-asserted-by":"publisher","unstructured":"Brown DM, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403:1153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(23)02577-1.","DOI":"10.1016\/S0140-6736(23)02577-1"},{"key":"4779_CR21","doi-asserted-by":"publisher","unstructured":"Lanzetta P, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1.","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"4779_CR22","unstructured":"Regeneron Pharmaceuticals Inc. EYLEA\u00ae HD (aflibercept) injection, for intravitreal use. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761355s001lbl.pdf."},{"key":"4779_CR23","unstructured":"Bayer AG. Eylea summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eylea."},{"key":"4779_CR24","unstructured":"New Pre-Filled Syringe for EYLEA 8 mg, EYLEA 8 mg intraocular injection kit 114.3 mg\/mL. 2024. https:\/\/www.santen.com\/en\/news\/2025\/2025_1\/20250521_1#:~:text=May%2021%2C%202025%20%E2%80%93%20Osaka%2C%20Japan%20%E2%80%93%20Santen,kit%20114.3%20mg%2FmL%20%28hereinafter%20EYLEA%C2%AE%208mg%20pre-filled%20syringe%29."},{"key":"4779_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2025.08.022","volume":"133","author":"JF Korobelnik","year":"2026","unstructured":"Korobelnik JF, et al. Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial. Ophthalmology. 2026;133:39\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.022.","journal-title":"Ophthalmology"},{"key":"4779_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ophtha.2025.10.028","volume":"133","author":"DV Do","year":"2026","unstructured":"Do DV, et al. Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2\/3 PHOTON Trial. Ophthalmology. 2026;133:577\u201388. https:\/\/doi.org\/10.1016\/j.ophtha.2025.10.028.","journal-title":"Ophthalmology"},{"key":"4779_CR27","first-page":"1857","volume":"66","author":"C Bailey","year":"2025","unstructured":"Bailey C, et al. SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with pretreated neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2025;66:1857.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4779_CR28","first-page":"440","volume":"66","author":"V Konidaris","year":"2025","unstructured":"Konidaris V, et al. SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with treatment-na\u00efve neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2025;66:440.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4779_CR29","first-page":"2391","volume":"66","author":"A Lobo","year":"2025","unstructured":"Lobo A, et al. SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with treatment-na\u00efve diabetic macular edema. Invest Ophthalmol Vis Sci. 2025;66:2391.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4779_CR30","first-page":"2392","volume":"66","author":"T Dervos","year":"2025","unstructured":"Dervos T, et al. SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with pretreated diabetic macular edema. Invest Ophthalmol Vis Sci. 2025;66:2392.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4779_CR31","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41433-026-04260-3","volume":"40","author":"C Bailey","year":"2026","unstructured":"Bailey C, et al. SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration. Eye. 2026;40:735\u20138. https:\/\/doi.org\/10.1038\/s41433-026-04260-3.","journal-title":"Eye"},{"key":"4779_CR32","first-page":"698","volume":"66","author":"A Donia","year":"2025","unstructured":"Donia A, Scrivens B, Salvatore S. Real-world efficacy, safety, and durability of aflibercept 8 mg in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2025;66:698.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4779_CR33","first-page":"2397","volume":"66","author":"AH Bedan","year":"2025","unstructured":"Bedan AH, et al. Efficacy and Safety of Aflibercept 8mg in Treating Diabetic Macular Oedema: Real World Data. Invest Ophthalmol Vis Sci. 2025;66:2397.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4779_CR34","unstructured":"Within3, <https:\/\/within3.com\/> (2026)."},{"key":"4779_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000381221","volume":"233","author":"J Pinheiro-Costa","year":"2015","unstructured":"Pinheiro-Costa J, et al. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice. Ophthalmologica. 2015;233:155\u201361. https:\/\/doi.org\/10.1159\/000381221.","journal-title":"Ophthalmologica"},{"key":"4779_CR36","doi-asserted-by":"publisher","unstructured":"Lee WK, et al. Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial. JAMA Ophthalmol. 2025 https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.5098.","DOI":"10.1001\/jamaophthalmol.2025.5098"},{"key":"4779_CR37","first-page":"2339","volume":"66","author":"G Ghorayeb","year":"2025","unstructured":"Ghorayeb G. Aflibercept 8 mg in diabetic macular edema: 156-week results from the PHOTON extension study. Invest Ophthalmol Vis Sci. 2025;66:2339.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4779_CR38","first-page":"6219","volume":"65","author":"D Sambhara","year":"2024","unstructured":"Sambhara D. Impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME): post hoc analysis of the phase 2\/3 PHOTON trial. Invest Ophthalmol Vis Sci. 2024;65:6219.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4779_CR39","doi-asserted-by":"publisher","unstructured":"Gale R, et al. Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Guidance from a UK expert panel. Eye. 2026;40:959\u201365. https:\/\/doi.org\/10.1038\/s41433-025-04180-8.","DOI":"10.1038\/s41433-025-04180-8"},{"key":"4779_CR40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","volume":"34","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, et al. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. Eye. 2020;34:480\u201390. https:\/\/doi.org\/10.1038\/s41433-019-0522-z.","journal-title":"Eye"},{"key":"4779_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","volume":"232","author":"MR Starr","year":"2021","unstructured":"Starr MR, et al. Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting. Am J Ophthalmol. 2021;232:90\u201397. https:\/\/doi.org\/10.1016\/j.ajo.2021.06.030.","journal-title":"Am J Ophthalmol"},{"key":"4779_CR42","doi-asserted-by":"publisher","first-page":"e000957","DOI":"10.1136\/bmjophth-2021-000957","volume":"7","author":"V Sheth","year":"2022","unstructured":"Sheth V, D\u2019Rozario M, Gune S, Blotner S. Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmol. 2022;7:e000957. https:\/\/doi.org\/10.1136\/bmjophth-2021-000957.","journal-title":"BMJ Open Ophthalmol"},{"key":"4779_CR43","doi-asserted-by":"publisher","first-page":"e42014","DOI":"10.1371\/journal.pone.0042014","volume":"7","author":"M Menghini","year":"2012","unstructured":"Menghini M, et al. Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration. PLoS ONE. 2012;7:e42014. https:\/\/doi.org\/10.1371\/journal.pone.0042014.","journal-title":"PLoS ONE"},{"key":"4779_CR44","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","volume":"122","author":"GS Ying","year":"2015","unstructured":"Ying GS, et al. Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2015;122:2523\u201331.e2521. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.015.","journal-title":"Ophthalmology"},{"key":"4779_CR45","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.oret.2023.02.008","volume":"7","author":"K Xue","year":"2023","unstructured":"Xue K, et al. Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmol Retin. 2023;7:564\u201372. https:\/\/doi.org\/10.1016\/j.oret.2023.02.008.","journal-title":"Ophthalmol Retin"},{"key":"4779_CR46","unstructured":"Garweg JG, Do DV, Korobelnik JF, et al. A pooled analysis of the CANDELA, PHOTON, and PULSAR trials through 96 weeks: comparably low intraocular inflammation (IOI)-related events with aflibercept 8 mg and 2 mg. Invest Ophthalmol Vis Sci. 2025;66:3070."},{"key":"4779_CR47","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41433-025-03765-7","volume":"39","author":"V Sarao","year":"2025","unstructured":"Sarao V, Veritti D, Bonini F, Martin AA, Lanzetta P. Early intraocular pressure dynamics following aflibercept 8 mg versus aflibercept 2 mg: a propensity score-matched analysis. Eye. 2025;39:1933\u20139. https:\/\/doi.org\/10.1038\/s41433-025-03765-7.","journal-title":"Eye"},{"key":"4779_CR48","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/bjo-2024-326053","volume":"109","author":"A Paris","year":"2025","unstructured":"Paris A, et al. Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study. Br J Ophthalmol. 2025;109:600\u20135. https:\/\/doi.org\/10.1136\/bjo-2024-326053.","journal-title":"Br J Ophthalmol"},{"key":"4779_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70269-7","volume":"10","author":"VA de Vries","year":"2020","unstructured":"de Vries VA, Bassil FL, Ramdas WD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020;10:13248. https:\/\/doi.org\/10.1038\/s41598-020-70269-7.","journal-title":"Sci Rep"},{"key":"4779_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","volume":"239","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski A, et al. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica. 2018;239:181\u201393. https:\/\/doi.org\/10.1159\/000486145.","journal-title":"Ophthalmologica"},{"key":"4779_CR51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaophthalmol.2025.0969","volume":"143","author":"KE Binder","year":"2025","unstructured":"Binder KE, Bleidissel N, Charbel Issa P, Maier M, Coulibaly LM. Noninfectious Intraocular Inflammation After Intravitreal Aflibercept. JAMA Ophthalmol. 2025;143:499\u2013506. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.0969.","journal-title":"JAMA Ophthalmol"},{"key":"4779_CR52","doi-asserted-by":"publisher","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025;10:e002091. https:\/\/doi.org\/10.1136\/bmjophth-2024-002091.","DOI":"10.1136\/bmjophth-2024-002091"},{"key":"4779_CR53","unstructured":"Regeneron Pharmaceuticals, Inc. Three-year Results for EYLEA HD\u00ae (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema. 2024. https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/three-year-results-eylea-hdr-aflibercept-injection-8-mg."},{"key":"4779_CR54","doi-asserted-by":"publisher","unstructured":"Bates BA, et al. The Efficacy and Safety of Intravitreal Aflibercept 8 mg in Clinical Practice. J Vitreoretin Dis. 2025;24741264251383384, https:\/\/doi.org\/10.1177\/24741264251383384.","DOI":"10.1177\/24741264251383384"},{"key":"4779_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00768-0","volume":"12","author":"LN Stoehr","year":"2025","unstructured":"Stoehr LN, et al. Intraocular inflammation following aflibercept 8 mg: real-world data from a multicentre retrospective observational study. Int J Retin Vitreous. 2025;12:6. https:\/\/doi.org\/10.1186\/s40942-025-00768-0.","journal-title":"Int J Retin Vitreous"},{"key":"4779_CR56","doi-asserted-by":"publisher","unstructured":"Palm C, Zweifel SA, Gabathuler F, Cozzi M, Fasler K. Efficacy of Aflibercept 8 mg in Pretreated Age-Related Macular Degeneration. J Clin Med 2025;14, https:\/\/doi.org\/10.3390\/jcm14144900.","DOI":"10.3390\/jcm14144900"},{"key":"4779_CR57","doi-asserted-by":"publisher","unstructured":"Barbosa GCS, et al. Real-World Functional and Anatomic Outcomes With Aflibercept 8.0 mg in Patients With Diabetic Macular Edema. J Vitreoretin Dis. 2025;24741264251376918, https:\/\/doi.org\/10.1177\/24741264251376918.","DOI":"10.1177\/24741264251376918"},{"key":"4779_CR58","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1055\/a-2655-8854","volume":"242","author":"M Grun","year":"2025","unstructured":"Grun M, Rothaus K, Lommatzsch AP, Faatz H. Early Outcome of Aflibercept 8 mg for Neovascular AMD in the Real-world Setting. Klin Monbl Augenheilkd. 2025;242:1224\u201332. https:\/\/doi.org\/10.1055\/a-2655-8854.","journal-title":"Klin Monbl Augenheilkd"},{"key":"4779_CR59","doi-asserted-by":"publisher","unstructured":"Abu Ishkheidem I, et al. Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration. Acta Ophthalmol. 2025; https:\/\/doi.org\/10.1111\/aos.17590.","DOI":"10.1111\/aos.17590"},{"key":"4779_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00665-6","volume":"11","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, De Oliveira Figueiredo EC, Montesel A, Vermeirsch S, Eandi CM. Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Naive neovascular AMD: AI-assisted fluid volume analysis. Int J Retin Vitreous. 2025;11:42. https:\/\/doi.org\/10.1186\/s40942-025-00665-6.","journal-title":"Int J Retin Vitreous"},{"key":"4779_CR61","first-page":"3110","volume":"66","author":"T Leng","year":"2025","unstructured":"Leng T, et al. Early insights from real-world use of aflibercept 8 mg among eyes with neovascular age-related macular degeneration (nAMD) switching from other anti-VEGF agents. Invest Ophthalmol Vis Sci. 2025;66:3110.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4779_CR62","doi-asserted-by":"publisher","unstructured":"Musadiq M, et al. Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom. Life. 2025;15:903. https:\/\/doi.org\/10.3390\/life15060903.","DOI":"10.3390\/life15060903"}],"updated-by":[{"DOI":"10.1038\/s41433-026-04887-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000}}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04779-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04779-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04779-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:38:24Z","timestamp":1792561104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04779-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":62,"alternative-id":["4779"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04779-5","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article typos have corrected in the Introduction, Methods section, tab. 1., Clinical caution paragraph, Section 5 Statement 12, Reference 7 and 8 on page 7, Reference 20, 21, 24, 39, 46, 52, 53, 57, 59, and 63 on page 8, and Competing interest section.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41433-026-04887-2","URL":"https:\/\/doi.org\/10.1038\/s41433-026-04887-2","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AL reported consulting fees from 4DMT, AbbVie, Adverum, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim, Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire Pharma, Opthea, Roche and Voiant. AS reported consulting fees from Allergan, Apellis, Bayer, Novartis and Roche. CCW reported consulting fees and research funding from Bayer, EyeBiotech, Genentech, Kodiak, Novartis and Regeneron. CMGC reported consulting fees, speaker fees and grant funding from Bayer, Roche, Novartis, Boehringer Ingelheim, Topcon, Zeiss, Janssen and Avirmax. Member of the Eye editorial board. DE reported speaker fees from Astellas, Apellis, Bayer, Genentech and Regeneron Pharmaceuticals Inc.; consulting fees from 4D Molecular Therapeutics, AAVantgarde Bio, AbbVie, Adverum, Akari, Alexion, Amaros, ANI, Annexon, Apellis, Astellas, Bausch & Lomb, Bayer, Bitfount, Boehringer Ingelheim, Complement Therapeutics, EcoR1, Emmes, EyePoint, Focus\/Skyline, Genentech, Harrow, Imvionix, Kodiak, Kriya, Lexitas, Nanoscope, Neurotech, Notal Vision, Novartis, Ocugen, Ocular Therapeutix, Ollin, Opthea, Orasis, PPD ThermoFisher, Regeneron Pharmaceuticals Inc., Regenxbio, ReVive, RetinAI, Roche, Samsara, Surrozen, Stealth, Stoke, Tilak, Unity; research funding from 4D Molecular Therapeutics, AbbVie, Adverum, Aerie\/Alcon, Alexion, Allegenesis, Amaros, Annexon, Apellis, Astellas, Aviceda, Bayer, Boehringer Ingelheim, EyeBio, Eyepoint, Focus\/Skyline, Genentech, Ionis, Janseen, Kodiak, Kyowa Kirin, Novartis, Ocular Therapeutix, Oculis, Ollin, Opthea, ONL, Priovant, Regeneron Pharmaceuticals Inc., Regenxbio, RetinAI, Roche, Stealth, Unity; is a stockholder for\/has equity in 4D Molecular Therapeutics, Amaros, Boston Image Reading Center, Eyepoint, Hemera Biosciences, Ollin, ReVive and USRetina. FGH reported consultancy fees from AbbVie, Acucela, Alcon, Alexion, Alnylam, Annexon, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Cirrus, Eyepoint, Galimedix, Genentech\/Roche, Grayburg Vision, Heidelberg Engineering, Lin Bioscience, Jansen, Merck, Novartis, Oculis, Okuvision, Opthea, Oxurion, Sanofi, Science, Stealth Biotherapeutics, RetinAI, TenPoint, Topcon, and Zeiss; and financial support from Acucela, AbbVie, Allergan, Annexon, Apellis, Astellas, Bayer, Bioeq, Centervue, Geuder, Genentech\/Roche, Heidelberg Engineering, NightStar, Novartis, Science, Zeiss and 4D Molecular Therapeutics. J-FK reported consulting fees from 4DMT, AbbVie, Adverum, Apellis, Bayer, Boehringer Ingelheim, Carl Zeiss Meditec, Eyepoint Pharma, Ocular Therapeutix, Roche, SeaBeLife and Thea; and is a member of DSMB: Complement Therapeutics and Novo Nordisk. JZ-V reported financial support and consultancy fees from AbbVie, Adverum, Alcon, Alimera Sciences, Bausch & Lomb, Bayer, Brill Pharma, DORC, Esteve, Novartis, Oxular, Preceyes, Roche, Sandoz, Topcon, ULMA Medical Technologies and Zeiss. Member of the Eye editorial board. MRM reported consulting fees from AbbVie, Alcon, Alimera, Allergan, Amgen, Apellis Pharmaceuticals, Astellas, Aviceda Therapeutics, Bayer, Boehringer Ingelheim, Dandelione, Evolve Medical Education, Eyegnos consulting, EyePoint Pharmaceuticals, GenSight Biologics, Isarna Therapeutics, Iveric Bio, Kubota, LumiThera, Novartis, Ocular Therapeutics, Oculis, OcuTerra Therapeutics, OD-OS, ONL Therapeutics, RetinAI, Roche, Sitalis, UBS analytics and Zeiss. MWS reported consulting fees from Alkahest, Bayer, Biogen, Revena, Regeneron and Bayer; and funding from Allergan, Kanghong and Regeneron. PL reported consulting fees from 4DMT, AbbVie, Adverum, Aerie, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, Celltrion, EyeBio, EyePoint Pharmaceuticals, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics and Roche. RG reported consulting fees from AbbVie, Advanz, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Novartis, Ocular Therapeutix, Outlook Therapeutics and Roche; and research funding from Bayer, Heidelberg Engineering, and Roche. SS reported funding\/fees from AbbVie, Alimera Science, Amgen, Apellis, Astellas, Ashvatta Therapeutics, Bayer, Biogen, Boehringer Ingelheim, Clearside Biomedical, Eyebiotech, Eyepoint Phamaceuticals, Iveric Bio, Janssen Pharmaceuticals, Nova Nordisk, Oculis, Optos, Ocular Therapeutix, Outlook Therapeutics, Kriya Therapeutics, OcuTerra, Ripple Therapeutics, Roche, Stealth Biotherapeutics, and Sanofi; and received financial support from AbbVie, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, 4DMT, Eyebiotech, Eyexora, Eyepoint Pharmaceuticals, Iveric Bio, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Oculis, Outlook Therapeutics, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi. TS reported consulting fees from AbbVie, Bayer, Boehringer Ingelheim, Chugai\/Roche, Jansen, Novartis, Senju, and Kiora. TYW reported consulting fees from Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Eden Ophthalmic, Genentech, Iveric Bio\/Astellas Pharma, Novartis, Oxurion, Plano, Roche, Sanofi, Shanghai Henlius and Zhaoke Pharmaceutical; and holds patents and is the co-founder of EyRiS and Visre. VC reported consulting fees from Apellis, Bayer, Boehringer Ingelheim, EyePoint Pharmaceuticals, Janssen, Novartis and Roche; and research funding from Bayer, Novartis and Roche. Member of the Eye editorial board.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}